Streetbeat News

INZY

Inozyme Pharma, Inc.

https://www.inozyme.com

Industry

Biotechnology

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Open

2.88

Mkt cap

179M

Volume

405K

High

2.94

P/E Ratio

-1.80

52-wk high

7.79

Low

2.75

Div yield

N/A

52-wk low

2.75

Inozyme Pharma (INZY) has experienced a significant decline of 29.98% over the past four weeks, placing it in oversold territory. However, the selling pressure may have subsided, and with Wall Street analysts raising earnings estimates, a trend reversal could be on the horizon.

Portfolio Pulse from

November 13, 2024 | 4:00 pm

Inozyme Pharma, a clinical-stage biopharmaceutical company, announced that its CEO, Doug Treco, will present at upcoming investor conferences. The company focuses on developing therapeutics for rare diseases affecting bone health and blood vessel function.

Portfolio Pulse from

November 11, 2024 | 1:45 pm

Needham analyst Joseph Stringer has reiterated a Buy rating on Inozyme Pharma (NASDAQ:INZY) and maintained a price target of $23.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2024 | 11:00 am

HC Wainwright & Co. has reiterated its Buy rating for Inozyme Pharma (NASDAQ:INZY) and maintained a price target of $14, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2024 | 10:51 am

Inozyme Pharma has reported positive interim data from its Phase 1 SEAPORT 1 trial of INZ-701, showing the treatment is well-tolerated and significantly increases PPi levels in ESKD patients on hemodialysis. The company plans a registrational trial in calciphylaxis for 2025.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 5:19 pm

Inozyme Pharma will present interim data from its Phase 1 SEAPORT 1 trial of INZ-701 for end-stage kidney disease at the ASN Kidney Week 2024.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 12:43 pm

Wedbush analyst David Nierengarten has reiterated an Outperform rating for Inozyme Pharma (NASDAQ:INZY) and maintained a price target of $15.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:18 pm

Inozyme Pharma presented new data at ASBMR 2024, emphasizing the urgent need for therapies for cardiovascular and musculoskeletal complications in ENPP1 and ABCC6 deficiencies. They also launched the PROPEL Registry to enhance understanding of these rare diseases.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 12:17 pm

Stifel has initiated coverage on Inozyme Pharma Inc. (NASDAQ:INZY) with a Buy rating and a $16 price target, highlighting its lead candidate INZ-701's potential in treating rare diseases. The FDA has granted fast track designation for INZ-701 for ABCC6 Deficiency, and the company plans a pivotal study by the end of 2024.

Portfolio Pulse from Vandana Singh

September 12, 2024 | 6:36 pm

Several Wall Street analysts initiated coverage on key stocks, including AutoNation, Rocket Lab USA, Sprouts Farmers Market, Inozyme Pharma, and Group 1 Automotive. Notably, AutoNation received an Overweight rating with a $210 price target, while Rocket Lab USA was rated Market Perform.

Portfolio Pulse from Avi Kapoor

September 12, 2024 | 11:43 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.